UK markets closed

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
1.2600-0.0300 (-2.33%)
At close: 04:00PM EST
1.2597 -0.00 (-0.02%)
After hours: 05:05PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.2900
Open1.3200
Bid1.2500 x 36900
Ask1.2600 x 305200
Day's range1.2500 - 1.3200
52-week range1.1200 - 2.5450
Volume32,289,462
Avg. volume22,412,021
Market cap2.695B
Beta (5Y monthly)1.42
PE ratio (TTM)N/A
EPS (TTM)-0.4100
Earnings date29 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.38
  • PR Newswire

    Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results

    Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2023. The update, including a webcast slide presentation and supplemental financial information, will be available at investors.ginkgobioworks.com.

  • Business Wire

    bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network

    CAMBRIDGE, England & BOSTON, February 28, 2024--bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network. The Network, launched today, is a groundbreaking ecosystem of cutting edge technology partners, committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer

  • PR Newswire

    Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions

    Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced that in connection to its transaction with Patch Biosciences, Inc. ("Patch Bio") on February 26, 2024, Ginkgo approved grants of restricted stock units with an aggregate grant date fair value of $4,292,000 to eight Patch Bio employees, and in connection with its acquisition of Reverie Labs, Inc. ("Reverie") on February 23, 2024, Ginkgo approved grants of restricted stock uni